Royalty Pharma plc has published the transcript of its third-quarter 2025 earnings call, held on November 5, 2025. The event brought together key executives, including the Chief Executive Officer, Chief Financial Officer, and other senior leadership, as well as analysts from firms such as Goldman Sachs, JPMorgan Chase, Citibank, and Evercore ISI. During the call, management reviewed the company's Q3 2025 financial results and discussed forward-looking statements, highlighting both recent achievements and ongoing strategic priorities. The Senior Vice President, Head of Investor Relations & Communications, opened the call by thanking participants and referring listeners to the earnings results and presentation slides available on the company's website. Management reminded participants that, "information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from these statements." The call included a discussion of key financial metrics, with management emphasizing the use of non-GAAP liquidity measures to provide greater transparency. Attendees were also advised to consult the company's most recent 10-K filing for a detailed description of risk factors. The full transcript can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.
Comments